Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital.
Int J Antimicrob Agents
; 59(1): 106481, 2022 Jan.
Article
en En
| MEDLINE
| ID: mdl-34801678
ABSTRACT
OBJECTIVES:
Due to recent safety concerns regarding fluoroquinolones and the potential medical and economic benefits, we investigated the efficacy of a single intravenous dose of 1.5 g azithromycin for the treatment of pulmonary legionellosis.METHODS:
Using a nationwide legionellosis registry for pre-selection, 74 patients admitted from 2000-2018 to a tertiary care hospital owing to pneumonia caused by Legionella pneumophila were retrospectively included in this study.RESULTS:
Conventional treatment regimens consisting of fluoroquinolones (n = 20), macrolides (n = 30) or combinations of both (n = 24) and a single intravenous dose of azithromycin (n = 12) have been demonstrated to be equally effective. Single-dose azithromycin treatment was well tolerated and resulted in a shorter hospital stay (P = 0.0464) and shorter antibiotic treatment duration (P = 0.0004) allowing earlier discharge.CONCLUSION:
A single intravenous dose of azithromycin might be a valuable treatment alternative for patients with legionellosis.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Legionelosis
/
Azitromicina
/
Fluoroquinolonas
/
Centros de Atención Terciaria
/
Antibacterianos
Tipo de estudio:
Observational_studies
País/Región como asunto:
Europa
Idioma:
En
Revista:
Int J Antimicrob Agents
Año:
2022
Tipo del documento:
Article